This abstract application is for posters to be displayed during the Pennsylvania Pharmacists Association’s 2018 Mid-Year Conference during a special CE session on Saturday, January 27, 2018. This application is to be submitted on or before December 1st, 2017 to Rachel Stall, PPA Membership and Program Coordinator. You will receive a confirmation that your application has been received within two business days of submission.

Please note that in order to be considered for acceptance for a poster presentation at PPA’s Mid-Year, this abstract application must be submitted by the deadline.

Title of Poster/Abstract: Alpha -Santalol inhibits migration of breast cancer cells by targeting β-catenin pathway

Poster/Abstract Developed by (list all involved in the development): Kacey Knapp, Abigail Nemeth, James Steigerwalt, Terra Landis, and Ajay Bommareddy
Lead Contact Name: Kacey Knapp
Lead Contact Phone: 607-761-3801
Lead Contact Email: Kacey.knapp@wilkes.edu

Pharmacy School: Wilkes University

Other students involved as co-presenters:

<table>
<thead>
<tr>
<th>Name</th>
<th>Email</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abigail Nemeth</td>
<td><a href="mailto:abigail.nemeth@wilkes.edu">abigail.nemeth@wilkes.edu</a></td>
</tr>
</tbody>
</table>

Preceptor/faculty member involved in the project/research review:

Name: Ajay Bommareddy
Email Address: ajay.bommareddy@wilkes.edu

Abstract (insert into this application. Do NOT submit separately.)

Please be sure to follow the submission criteria and guidelines for submission. These are available here: http://www.papharmacists.com/page/PosterPresentations Failure to do so could disqualify your application from consideration.
Abstract category: (select one and follow the guidelines for the respective category)

☒ Contributed Research Report OR Reports on Projects in Progress
☐ Innovative Practice Reports

Insert Abstract: (limited to 300 words – Please follow the order and guidelines)

Introduction: This study was undertaken to investigate the anticancer properties of α-santalol in cultured estrogen-independent (MDA-MB 231) and estrogen-dependent (MCF-7) breast cancer cells. α-Santalol, a terpenoid found in sandalwood oil has been shown to inhibit breast cancer cell growth in vitro by inducing apoptosis. Methods: Expression of major proteins examined in the study was determined using standard Western blot protocol and analyzed by LICOR-Odyssey infra-red scanner. Localization of β-catenin in the cells was analyzed using immunofluorescence assay. Migration of cells was determined employing wound-healing and Boyden chamber migration assay. Results: Treatment of breast cancer cells with α-santalol (20, 40 μM) resulted in a decrease in the cellular migration when compared with DMSO (control) treated cells. α-santalol treatment also reduced the expression of phospho β-catenin levels and prevented the localization of β-catenin from cytosol to nucleus. Conclusion: This study revealed that α-santalol inhibited migration of breast cancer cells by targeting β-catenin pathway. Future studies include elucidating the role of alpha-santalol on pathways regulating angiogenesis and metastasis. This study, in part was supported by Wilkes University mentoring grant and Provost Research and Scholarship grant.

Additional Documentation needed, at a later date:
By submitting this abstract application, submitter is agreeing to provide the following by the deadline in advance of the Mid Year Conference. If your abstract is accepted, all of the following documentation and information is necessary for your poster to be presented at Mid-Year: (Please note we will include these details as a reminder in your acceptance acknowledgement which will be sent on or before January 20, 2017.)

ALL MUST BE RECEIVED PRIOR TO THE MID YEAR CONFERENCE OR YOUR POSTER CANNOT BE DISPLAYED:
☑ Signed Acknowledgement by Faculty/Preceptor
☑ List of 6 to 8 questions for CE
☑ Presenter(s) Disclosure
☑ Electronic submission of your poster

*Please note PPA does accept encore presentations.

Please email your application – all in one document to: rstall@papharmacists.com by December 1st, 2017. Submissions will receive a confirmation of receipt ONLY by Rachel within two business days of submission. This receipt confirmation is NOT a notice of Acceptance.

*There is a limit of 40 posters so posters meeting the required criteria and approved will be accepted on a first-come, first-serve basis.*

Acceptance notices will be sent on or before December 20, 2017,
with the final details for the on-site poster presentation.